Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | ECMO | Research

Impact of recipient and donor pretransplantation body mass index on early postosperative complications after lung transplantation

Authors: E. Atchade, C. De Tymowski, E. Lepitre, N. Zappella, A. Snauwaert, S. Jean-Baptiste, A. Tran-Dinh, B. Lortat-Jacob, J. Messika, H. Mal, P. Mordant, Y. Castier, S. Tanaka, P. Montravers

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Prior studies have assessed the impact of the pretransplantation recipient body mass index (BMI) on patient outcomes after lung transplantation (LT), but they have not specifically addressed early postoperative complications. Moreover, the impact of donor BMI on these complications has not been evaluated. The first aim of this study was to assess complications during hospitalization in the ICU after LT according to donor and recipient pretransplantation BMI.

Methods

All the recipients who underwent LT at Bichat Claude Bernard Hospital, Paris, between January 2016 and August 2022 were included in this observational retrospective monocentric study. Postoperative complications were analyzed according to recipient and donor BMIs. Univariate and multivariate analyses were also performed. The 90-day and one-year survival rates were studied. P < 0.05 was considered to indicate statistical significance. The Paris-North Hospitals Institutional Review Board approved the study.

Results

A total of 304 recipients were analyzed. Being underweight was observed in 41 (13%) recipients, a normal weight in 130 (43%) recipients, and being overweight/obese in 133 (44%) recipients. ECMO support during surgery was significantly more common in the overweight/obese group (p = 0.021), as were respiratory complications (primary graft dysfunction (PGD) (p = 0.006), grade 3 PDG (p = 0.018), neuroblocking agent administration (p = 0.008), prone positioning (p = 0.007)), and KDIGO 3 acute kidney injury (p = 0.036). However, pretransplantation overweight/obese status was not an independent risk factor for 90-day mortality. An overweight or obese donor was associated with a decreased PaO2/FiO2 ratio before organ donation (p < 0.001), without affecting morbidity or mortality after LT.

Conclusion

Pretransplantation overweight/obesity in recipients is strongly associated with respiratory and renal complications during hospitalization in the ICU after LT.
Appendix
Available only for authorised users
Literature
1.
2.
Chambers DC, Perch M, Zuckermann A, Cherikh WS, Harhay MO, Hayes D, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-eighth adult lung transplantation report—2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1060–72.CrossRefPubMedPubMedCentral
3.
Lederer DJ, Wilt JS, D’Ovidio F, Bacchetta MD, Shah L, Ravichandran S, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med. 2009;180(9):887–95.CrossRefPubMedPubMedCentral
4.
Madill J, Gutierrez C, Grossman J, Allard J, Chan C, Hutcheon M, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90–day mortality following transplantation. J Heart Lung Transplant. 2001;20(3):288–96.CrossRefPubMed
5.
Culver DA, Mazzone PJ, Khandwala F, Blazey HC, DeCamp MM, Chapman JT. Discordant utility of ideal body weight and body mass index as predictors of mortality in lung transplant recipients. J Heart Lung Transplant. 2005;24(2):137–44.CrossRefPubMed
6.
Kanasky WF, Anton SD, Rodrigue JR, Perri MG, Szwed T, Baz MA. Impact of body weight on long-term survival after lung transplantation. Chest. 2002;121(2):401–6.CrossRefPubMed
7.
González-Castro A, Llorca J, Suberviola B, Díaz-Regañón G, Ordóñez J, Miñambres E. Influence of nutritional status in lung transplant recipients. Transplant Proc. 2006;38(8):2539–40.CrossRefPubMed
8.
Allen JG, Arnaoutakis GJ, Weiss ES, Merlo CA, Conte JV, Shah AS. The impact of recipient body mass index on survival after lung transplantation. J Heart Lung Transplant. 2010;29(9):1026–33.CrossRefPubMed
9.
Singer JP, Peterson ER, Snyder ME, Katz PP, Golden JA, D’Ovidio F, et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med. 2014;190(9):1012–21.CrossRefPubMedPubMedCentral
10.
Fernandez R, Safaeinili N, Kurihara C, Odell DD, Jain M, DeCamp MM, et al. Association of body mass index with lung transplantation survival in the United States following implementation of the lung allocation score. J Thorac Cardiovasc Surg. 2018;155(4):1871–1879.e3.CrossRefPubMed
11.
Chaikriangkrai K, Jhun H, Graviss E, Jyothula S. Overweight-mortality paradox and impact of six-minute walk distance in lung transplantation. Ann Thorac Med. 2015;10(3):169.CrossRefPubMedPubMedCentral
12.
Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the pulmonary transplantation council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1–15.CrossRefPubMed
13.
Van Raemdonck D, Neyrinck A, Verleden GM, Dupont L, Coosemans W, Decaluwé H, et al. lung donor selection and management. Proc Am Thorac Soc. 2009;6(1):28–38.CrossRefPubMed
14.
Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003;22(11):1183–200.CrossRefPubMed
15.
Snell GI, Yusen RD, Weill D, Strueber M, Garrity E, Reed A, et al. Report of the ISHLT working group on primary lung graft dysfunction, part i: definition and grading—a 2016 consensus group statement of the international society for heart and lung transplantation. J Heart Lung Transplant. 2017;36(10):1097–103.CrossRefPubMed
16.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–184.CrossRefPubMed
17.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.CrossRefPubMedPubMedCentral
18.
Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J heart lung transplant. 2007;26(12):1229–42.CrossRefPubMed
19.
Atchade E, Barour S, Tran-Dinh A, Jean-Baptiste S, Tanaka S, Tashk P, et al. Acute kidney injury after lung transplantation: perioperative risk factors and outcome. Transplant Proc. 2020;52(3):967–76.CrossRefPubMed
20.
Atchade E, Arsène A, Jean-Baptiste S, Tran Dinh A, Tanaka S, Stern J, et al. Donors brain-dead after successful resuscitation of cardiac arrest: Early outcome and postoperative complications of lung recipients. Resuscitation. 2023;184: 109720.CrossRefPubMed
21.
22.
Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1042–55.CrossRefPubMedPubMedCentral
23.
Anderson MR, Cantu E, Shashaty M, Benvenuto L, Kalman L, Palmer SM, et al. Body mass index and cause-specific mortality after lung transplantation in the United States. Ann Am Thorac Soc. 2023;20(6):825–33.CrossRefPubMed
24.
Shah RJ, Diamond JM, Cantu E, Flesch J, Lee JC, Lederer DJ, et al. Objective estimates improve risk stratification for primary graft dysfunction after lung transplantation. Am J Transplant. 2015;15(8):2188–96.CrossRefPubMedPubMedCentral
25.
Lederer DJ, Kawut SM, Wickersham N, Winterbottom C, Bhorade S, Palmer SM, et al. Obesity and primary graft dysfunction after lung transplantation: the lung transplant outcomes group obesity study. Am J Respir Crit Care Med. 2011;184(9):1055–61.CrossRefPubMedPubMedCentral
26.
Whitson BA, Prekker ME, Herrington CS, Whelan TPM, Radosevich DM, Hertz MI, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007;26(10):1004–11.CrossRefPubMed
27.
Hoffman SA, Wang L, Shah CV, Ahya VN, Pochettino A, Olthoff K, et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009;9(2):389–96.CrossRefPubMed
28.
Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes. 2010;34(5):791–9.CrossRef
29.
Keller H, van der Schueren MAE, Consortium GLIM, Jensen GL, Barazzoni R, Compher C, et al. Global leadership initiative on malnutrition glim guidance on validation of the operational criteria for the diagnosis of protein‐energy malnutrition in adults. J Parenter Enter Nutr. 2020;44(6):992–1003.CrossRef
30.
National Cholesterol Education Program (NCEP) Expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the national cholesterol education program (NCEP) Expert panel on detection Evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.CrossRef
31.
Karelis AD, Rabasa-Lhoret R. Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab. 2008;34(2):183–4.CrossRefPubMed
Metadata
Title
Impact of recipient and donor pretransplantation body mass index on early postosperative complications after lung transplantation
Authors
E. Atchade
C. De Tymowski
E. Lepitre
N. Zappella
A. Snauwaert
S. Jean-Baptiste
A. Tran-Dinh
B. Lortat-Jacob
J. Messika
H. Mal
P. Mordant
Y. Castier
S. Tanaka
P. Montravers
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02977-z

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue

Research

Exploring the causal relationship between immune cells and idiopathic pulmonary fibrosis: a bi-directional Mendelian randomization study

Research

Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer

Research

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

Research

Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak

Research

Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study

Research

A comparative study of bronchodilator response: utilizing pre-bronchodilator versus predicted normal values
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits